Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. economy, expands America's global trade, and attracts foreign companies to base operations in the U.S.

Competitive Advantage 15

Competitive Advantage Globalization Development Intellectual Capital 15

Harvard Business Review

JULY 11, 2018

To focus on businesses that are closer in spirit to the prototypical high-tech startup, we used a variety of indicators: whether the firm was granted a patent, received VC investment, or operated in an industry that employs a high fraction of STEM workers. In light of this evidence, why do some VCs persist in betting on young founders?

Succession 15

Succession IPO Entrepreneur Biotechnology 15

Harvard Business Review

SEPTEMBER 14, 2011

Chirotech specializes in biocatalysis and chemocatalysis, two important subspecialties of biotechnology and chemistry that help develop key biological and chemical intermediates needed for the efficient production of medicines. You can't run your global R&D operations from headquarters in Mumbai. and the U.K.

Globalization 11

Globalization Innovation Decentralization Chemicals 11

Harvard Business Review

JULY 16, 2013

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., The industry breakout was done using eight major sectors (similar to those in the Global Industry Classification Standard system): Consumer Discretionary (e.g., banking & financial services, insurance, real estate); Health Care (e.g.,

Telecommunications 10

Telecommunications Health Care Biotechnology Real Estate 10

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They’re also sharing risk. The new business model has yet to solidify, and the leaders have yet to emerge. The positions are there for the taking. But not for long. The options are tangible.

Health Care 9

Health Care Pharmaceuticals Information Technology Supply Chain 9

Harvard Business Review

FEBRUARY 3, 2015

Uzzi and another colleague, Jarrett Spiro, also discovered that this pattern held across sectors as disparate as the Broadway mu­sical industry and biotechnology. Learn more about your market value. He then mapped out the network of who consulted with whom. Be a guest speaker at a local or national event. Start a blog.

How To 8

How To Diversity Letter Learning-by-Doing 8

Harvard Business Review

OCTOBER 26, 2011

Their behavior displays promising parallels to the early days of the biotechnology industry. When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive.

Energy 14

Energy Finance IPO Biotechnology 14

Harvard Business Review

MARCH 28, 2012

billion to acquire the webOS operating system, Hewlett-Packard discontinued its webOS-based series of smartphones and line of Touchpad tablets — losing its bet on a webOS-everywhere future. This means they're buying drugs that could be similar to others already on or coming soon to the market.

Innovation 14

Innovation Company Biotechnology CFO 14

Harvard Business Review

MARCH 17, 2014

An estimated 250 funds are actively raising capital in a market that the Global Impact Investing Network estimates at $25 billion. As the sector grows through this period of creative destruction, models that don’t work will die out, models that survive will attract copycats, operating costs will go down, and winners will rise to the top.

Development 11

Development Microfinance Biotechnology Exit Strategy 11

The Horizons Tracker

NOVEMBER 29, 2023

According to a study conducted by the Indiana University Kelley School of Business, diversity in terms of gender, race, and ethnicity has proven to be beneficial for companies operating in the United States. “We looked at their experiences and not just their demographic background—the more functional aspect of diversity.

Diversity 111

Diversity Innovation Biotechnology Short-term 111

Harvard Business Review

MARCH 5, 2012

Thus, the decline of manufacturing is not completely a result of "natural" market forces. This tight connection between R&D, innovation, and production is present in sectors like biotechnology, advanced materials, and nanotechnology. By subsidizing other industries so generously, we have tilted the scales away from manufacturing.

Health Care 10

Health Care Biotechnology Industry Policies 10

Harvard Business Review

JUNE 16, 2016

To understand the nature of the problem, let’s look at how penicillin was brought to market. “But here, we can operate within the time frame of the next coffee break.” Profit-driven companies, on the other hand, feel so much pressure to go to market that they often pass on ideas with vast potential.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

MAY 15, 2015

Mary Shelley told us nothing about the future of biotechnology, but the popularity and plausibility of Frankenstein: The Modern Prometheus tells us a lot about 1818’s fears and aspirations for technology and its relation to society. Taken as a whole, science fiction’s predictions do not outperform random chance.

Class 8

Class Open-book Politics Biotechnology 8

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. When Intuitive Surgical launched the Da Vinci System medical robot — which allows surgeons to operate using 3-D visualization and four robotic arms — the company faced significant technical as well as demand uncertainty.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22